Safety and Efficacy of I(131) Tositumomab in the Treatment of Non-Hodgkin's Lymphoma

Clinical Medicine. Therapeutics
doi 10.4137/cmt.s2124
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

131-Iodine Tositumomab in Lymphoma

Current Oncology
Oncology
2009English

Tositumomab and Iodine I 131 Tositumomab (Bexaar)

American Journal of Neuroradiology
MedicineNuclear MedicineNeurologyImagingRadiology
2011English

The Epidemiology of Non-Hodgkin's Lymphoma

Oncogene
Cancer ResearchGeneticsMolecular Biology
2004English

Assessment of Treatment-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia in Patients With Non-Hodgkin Lymphoma Treated With Tositumomab and Iodine I131 Tositumomab

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Liquid Biopsy in Non‐Hodgkin's Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Myeloablative I-131-Tositumomab With Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years With B Cell Lymphoma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

DNA Content and Prognosis of Non-Hodgkin's Lymphoma

British Journal of Cancer
Cancer ResearchOncology
1987English

Primary Non Hodgkin's Lymphoma of the Lacrimal Sac

World Journal of Surgical Oncology
SurgeryOncology
2007English

Classification of Non‐Hodgkin's Lymphoma: A Proposal

Oncologist
Cancer ResearchMedicineOncology
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy